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1.1. Background on neonatal encephalopathy
To improve comparability of vaccine safety data, the acute
neonatal encephalopathy working group has developed a case
definition and guidelines neonatal encephalopathy applicable in
study settings with different availability of resources, in healthcare
settings that differ by availability of and access to health care, and
in different geographic regions.
The definition and guidelines were developed through group
consensus. They are grounded on both expert opinion and asystematic literature review related to the assessment of acute
neonatal encephalopathy as an adverse event following immunisa-
tion and to the diagnosis of acute neonatal encephalopathy in
humans.
Encephalopathy is a general term used to define disease,
malfunction or damage of the brain. The major symptom of
encephalopathy is an altered mental state [1]. Defining altered
mental state in the newborn is significantly more challenging than
in the adult and there are no established direct measures to deter-
mine level of consciousness in the newborn. Nevertheless, specific
clinical signs reflecting neurological function correlate with the
overall severity of the encephalopathy. These clinical signs have
been grouped in stages, usually three of them: mild, moderate
and severe as in the Sarnat classification. The Sarnat criteria remain
as the most commonly accepted classification [2,3].
Neonatal encephalopathy has several potential etiologies and
acute hypoxia-ischemia is the most studied cause. Over the years,
the term ‘‘neonatal encephalopathy”, has been used by many as a
3 For Seizure definition see Ref. [12].
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that other etiologies are often reported as a specific diagnosis, as
in the case of inborn errors of metabolism (e.g. non-ketotic hyper-
glycinemia), infections (e.g. meningitis) and other specific causes.
It is therefore imperative to emphasize that many different pro-
cesses leading to neonatal encephalopathy may develop prenatally,
at birth or immediately post-delivery, and result from mainly, but
not exclusively, genetic, metabolic, infectious, and traumatic pro-
cesses. The common denominator in neonatal encephalopathy is
the loss of homeostasis which can lead to abnormal brain function
and potentially to brain structural changes [2–4].
Investigations such as magnetic resonance Imaging and neuro-
physiological technologies such as electroencephalography and
evoked potentials are aids in exploring the severity and prognosis
of neonatal encephalopathy, but are not required for its diagnosis.
MRI brain can be reported normal in 15–30% of cases of
confirmed mild cases (Sarnat 1) of hypoxic ischemic encephalopa-
thy [1,5].
The EEG is the most specific test to confirm and diagnose that a
clinical paroxysm is epileptic in origin [9]. Electrographic
pathological patterns correlate with neonatal seizures during
seizure recording and subtle or subclinical seizures can often only
be diagnosed by EEG monitoring. Once anti-seizure medications
are administered, up to 58% of treated neonates exhibit electro-
clinical uncoupling, in which the clinical signs of their seizures van-
ish despite the persistence of subclinical electrographic seizures [9].
EEG however has important technical limitations in the record-
ing of some epileptic seizures, particularly those originating in
mesial or midline areas of the brain. Also EEG is not always readily
available for recording in the NICU. Amplitude integrated EEG
(aEEG) is becoming widely used by neonatologists. This recording
compresses the time scale of conventional EEG. It has lesser spatial
resolution and is less sensitive for the detection of neonatal sei-
zures compared to long term monitoring by conventional EEG
[10,11]. Abnormalities on the neonatal EEG such as discontinuity
of the background or central sharp waves are not specific and will
vary depending on external factors such as gestational age, body
temperature during therapeutic cooling and medications [7].
Therefore, as per World Health Organization guidelines on
neonatal seizures, the most practical method of diagnosis is the
clinical recognition of neonatal seizures [8].
The Task Force on Neonatal Encephalopathy group on Neonatal
Encephalopathy and Neurological outcome published in 2014 a
comprehensive document defining Neonatal encephalopathy as
‘‘a clinical syndrome in an infant born at or beyond 35 weeks of
gestation, manifested by a subnormal level of consciousness or
seizures, and often accompanied by difficulty with initiating and
maintaining respiration and depression of tone and reflexes” [5].
It was the consensus of our group to replace the word ‘‘conscious-
ness” with the word ‘‘alertness” since the definition of ‘‘conscious-
ness” is more vague. We also considered it necessary to include in
the definition the concept of multiple potential etiologies.
When assessing encephalopathy in a newborn younger than
35 weeks of gestation, normal neurological development may pre-
vent specific behavioral reactions and reflexes to be tested, making
semiology unreliable. Furthermore, the diagnosis of ‘‘encephalopa-
thy of prematurity” is heavily based on neuroanatomical changes
seen on MRI or autopsies rather than acute clinical signs [2,6].
Considering the limitations for diagnosing and timing encepha-
lopathies in the preterm newborn, this review defines Neonatal
encephalopathy as a clinical syndrome presenting with abnormal
functioning of the central nervous system, in the earliest days of
life in an newborn (up to 28 days of life) born at or beyond 35
weeks of gestation, manifested by an abnormal level of alertness
or seizures, and often accompanied by difficulty with initiating
and maintaining respiration and depression of tone that may bedue to a variety of etiologies including hypoxia/ischemia, meta-
bolic disturbance, or infection.
This definition is to be equally applied in vaccinated or unvac-
cinated populations.
1.2. Methods for the development of the case definition and guidelines
for data collection, analysis, and presentation for neonatal
encephalopathy as an adverse events following maternal
immunisation
Following the process described on the Brighton Collaboration
Website http://www.brightoncollaboration.org/internet/en/index/
process.html, the Brighton Collaboration Neonatal Encephalopathy
Working Group was formed in 2016 and included members of clin-
ical, academic, public health and industry background. The compo-
sition of the working and reference group as well as results of the
web-based survey completed by the reference group with
subsequent discussions in the working group can be viewed at:
http://www.brightoncollaboration.org/internet/en/index/working_
groups.html.
To guide the decision-making for the case definition and
guidelines, a literature search was performed using Embase.com
(Medline/PubMed + Embase); ClinicalKey (eBooks); ScienceDirect
(eBooks); StatRef (eBooks) and the Cochrane Library.
Several different research platforms were utilized in this search
for references focused on maternal vaccination and encephalopa-
thies. These platforms included electronic books, systematic
reviews, and other journal literature. The following three search
parameters which included a variety of synonyms were combined;
pregnancy, vaccines, and encephalopathy.
This search resulted in several general book chapters discussing
various types of neonatal encephalopathy. There were no Cochrane
reviews that focused on this topic. The journal literature search
produced 33 results that included subject headings or keywords
for vaccines, pregnancy and encephalopathy. The results were lim-
ited to those published since 2005. The results were further limited
to either reviews or major/prospective clinical studies.
1.3. Temporal versus causal association with maternal immunisation
There are no reports of encephalopathy following immunisation
in the pregnant woman or the newborn. There is hence no uni-
formly accepted definition of Neonatal Encephalopathy following
immunisations. This is a missed opportunity, as data comparability
across trials or surveillance systems would facilitate data interpre-
tation and promote the scientific understanding of the event.
1.4. Periodic review
Similar to all Brighton Collaboration case definitions and guide-
lines, review of the definition with its guidelines is planned on a
regular basis (i.e. every three to five years) or more often if needed.
3. Case definition of neonatal encephalopathy3
For All Levels of Diagnostic Certainty
Newborn (1–28 days) born at or beyond 35 weeks of gestation
Level 1 of diagnostic certainty (Definite)
Abnormal level of alertness or seizures (see footnote 1)
AND
Difficulty with initiating and maintaining respiration
AND
Depression of tone
5 The date and/or time of onset is defined as the time post immunisation, when the
first sign or symptom indicative for Neonatal Encephalopathy occurred. This may only
be possible to determine in retrospect.
6 The date and/or time of first observation of the first sign or symptom indicative
for Neonatal Encephalopathy can be used if date/time of onset is not known.
7 The date of diagnosis of an episode is the day post immunisation when the event
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Abnormal level of alertness or seizures
AND
Difficulty with initiating and maintaining respiration
OR
Depression of tone
Level 3 of diagnostic certainty (Possible)
Abnormal level of alertness or seizures without difficulty with
initiating and maintaining respiration nor depression of tone
3. Guidelines for data collection, analysis, and presentation of
generalized acute neonatal encephalopathy as an adverse event
following maternal immunisation
It was the consensus of the Brighton Collaboration Neonatal
Encephalopathy Working Group to recommend the following
guidelines to enable meaningful and standardized collection,
analysis, and presentation of information about Neonatal
encephalopathy. However, implementation of all guidelines might
not be possible in all settings. The availability of information may
vary depending upon resources, geographical region, and whether
the source of information is a prospective clinical trial, a post-
marketing surveillance or epidemiological study, or an individual
report of Neonatal encephalopathy. Also, as explained in more
detail in the overview paper, these guidelines have been devel-
oped by this working group for guidance only, and are not to be
considered a mandatory requirement for data collection, analysis,
or presentation.
3.1. Data collection
These guidelines represent a desirable standard for the collec-
tion of data on availability following maternal immunisation to
allow for comparability of data, and are recommended as an addi-
tion to data collected for the specific study question and setting.
The guidelines are not intended to guide the primary reporting of
Neonatal Encephalopathy to a surveillance system or study moni-
tor. Investigators developing a data collection tool based on these
data collection guidelines also need to refer to the criteria in the
case definition, which are not repeated in these guidelines.
3.1.1. Source of information/reporter
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(1) Date of report.
(2) Name and contact information of person reporting4 and/or
diagnosing the Neonatal Encephalopathy as specified by coun-
try-specific data protection law.
(3) Name and contact information of the investigator responsi-
ble for the subject, as applicable.
(4) Relation to the patient (e.g., immuniser [clinician, nurse],
family member [indicate relationship], other).
3.1.2. Vaccinee/control
3.1.2.1. Demographics. For all cases and/or all study participants
(including mothers and infants), as appropriate, the following
information should be recorded:
(5) Case/study participant identifiers (e.g. first name initial
followed by last name initial) or code (or in accordance with
country-specific data protection laws).4 If the reporting centre is different from the vaccinating centre, appropriate and
timely communication of the adverse event should occur.(6) Date of birth, age, and sex.
(7) For infants: Gestational age and birth weight.
3.1.2.2. Clinical and immunisation history. For all cases and/or all
study participants, as appropriate, the following information
should be recorded:
(8) Past medical history, including hospitalisations, underlying
diseases/disorders, pre-immunisation signs and symptoms
including identification of indicators for, or the absence of,
a history of allergy to vaccines, vaccine components or med-
ications; food allergy; allergic rhinitis; eczema; asthma.
(9) Any medication history (other than treatment for the event
described) prior to, during, and after immunisation
including prescription and non-prescription medication as
well as medication or treatment with long half-life or long
term effect. (e.g. immunoglobulins, blood transfusion and
immunosuppressants).
(10) Immunisation history (i.e. previous immunisations and any
adverse event following immunisation (AEFI)), in particular
occurrence of Acute Neonatal Encephalopathy after a previ-
ous maternal immunisation.
3.1.3. Details of the immunisation
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(11) Date and time of maternal immunisation(s).
(12) Description of vaccine(s) (name of vaccine, manufacturer, lot
number, dose (e.g. 0.25 mL, 0.5 mL, etc.) and number of dose
if part of a series of immunisations against the same
disease).
(13) The anatomical sites (including left or right side) of all
immunisations (e.g. vaccine A in proximal left lateral thigh,
vaccine B in left deltoid).
(14) Route and method of administration (e.g. intramuscular,
intradermal, subcutaneous, and needle-free (including type
and size), other injection devices).
(15) Needle length and gauge.
3.1.4. The adverse event
(16) For all cases at any level of diagnostic certainty and for
reported events with insufficient evidence, the criteria ful-
filled to meet the case definition should be recorded.
Specifically document:
(17) Clinical description of signs and symptoms of Neonatal
Encephalopathy, and if there was medical confirmation of
the event (i.e. patient seen by physician).
(18) Date/time of onset,5 first observation6 and diagnosis,7 end of
episode8 and final outcome.9
(19) Concurrent signs, symptoms, and diseases.
(20) Measurement/testingmet the case definition at any level.
8 The end of an episode is defined as the time the event no longer meets the case
definition at the lowest level of the definition.
9 E.g. recovery to pre-immunisation health status, spontaneous resolution, thera-
peutic intervention, persistence of the event, sequelae, death.
10 An
the foll
inpatien
results
birth de
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(e.g. temperature, blood pressure) – in particular those
indicating the severity of the event;
 Method of measurement (e.g. type of thermometer, oral
or other route, duration of measurement, etc.);
 Results of laboratory examinations, surgical and/or
pathological findings and diagnoses if present.(21) Treatment given for Neonatal Encephalopathy, especially
specify what and dosing.
(22) Outcome (see footnote 7) at last observation.
(23) Objective clinical evidence supporting classification of the
event as ‘‘serious”.10
(24) Exposures other than the immunisation 24 h before and
after immunisation (e.g. food, environmental) considered
potentially relevant to the reported event.
3.1.5. Miscellaneous/general
(25) The duration of surveillance for Neonatal encephalopathy
should be predefined based on
 Biologic characteristics of the vaccine e.g. live attenuated
versus inactivated component vaccines;
 Biologic characteristics of the vaccine-targeted disease;
 Biologic characteristics of Neonatal encephalopathy
including patterns identified in previous trials (e.g.
early-phase trials); and
 Biologic characteristics of the vaccinee (e.g. nutrition,
underlying disease like immunodepressing illness).11 To determine the appropriate category, the user should first establish, whether a
reported event meets the criteria for the lowest applicable level of diagnostic
certainty, e.g. Level three. If the lowest applicable level of diagnostic certainty of the
definition is met, and there is evidence that the criteria of the next higher level of
diagnostic certainty are met, the event should be classified in the next category. This
approach should be continued until the highest level of diagnostic certainty for a(26) The duration of follow-up reported during the surveillance
period should be predefined likewise. It should aim to con-
tinue to resolution of the event.
(27) Methods of data collection should be consistent within and
between study groups, if applicable.
(28) Follow-up of cases should attempt to verify and complete
the information collected as outlined in data collection
guidelines 1–24.
(29) Investigators of patients with Neonatal encephalopathy
should provide guidance to reporters to optimise the quality
and completeness of information provided.
(30) Reports of Neonatal encephalopathy should be collected
throughout the study period regardless of the time elapsed
between immunisation and the adverse event. If this is not
feasible due to the study design, the study periods during
which safety data are being collected should be clearly
defined.
3.2. Data analysis
The following guidelines represent a desirable standard for
analysis of data on Neonatal encephalopathy to allow for compara-
bility of data, and are recommended as an addition to data anal-
ysed for the specific study question and setting.
(31) Reported events should be classified in one of the following
five categories including the three levels of diagnostic
certainty. Events that meet the case definition should be
classified according to the levels of diagnostic certainty as
specified in the case definition. Events that do not meet
the case definition should be classified in the additional cat-
egories for analysis.AEFI is defined as serious by international standards if it meets one or more of
owing criteria: (1) it results in death, (2) is life-threatening, (3) it requires
t hospitalisation or results in prolongation of existing hospitalisation, (4)
in persistent or significant disability/incapacity, (5) is a congenital anomaly/
fect, and (6) is a medically important event or reaction.3.2.1. Event classification in 5 categories11
3.2.1.1. Event meets case definition.
(1) Level 1: Criteria as specified in the Neonatal encephalopathy
case definition (Definite)
(2) Level 2: Criteria as specified in the Neonatal encephalopathy
case definition (Possible)
(3) Level 3: Criteria as specified in the Neonatal encephalopathy
case definition (Probable)
3.2.2. Event does not meet case definition
3.2.2.1. Additional categories for analysis.
(4) Reported Neonatal encephalopathy with insufficient
evidence to meet the case definition12
(5) Not a case of Neonatal encephalopathy13
(32) The interval between immunisation and reported Neonatal
Encephalopathy could be defined as the date/time of mater-
nal immunisation to the date/time of onset (see footnote 3)
of the first symptoms and/or signs consistent with the
definition.
(33) The duration of a possible Neonatal Encephalopathy could
be analysed as the interval between the date/time of onset
(see footnote 2) of the first symptoms and/or signs consis-
tent with the definition and the end of episode (see footnote
6) and/or final outcome (see footnote 7). Whatever start and
ending are used, they should be used consistently within
and across study groups.
(34) If more than one measurement of a particular criterion is
taken and recorded, the value corresponding to the greatest
magnitude of the adverse experience could be used as the
basis for analysis. Analysis may also include other character-
istics like qualitative patterns of criteria defining the event.
(35) The distribution of data (as numerator and denominator
data) could be analysed in predefined increments (e.g. mea-
sured values, times), where applicable. Increments specified
above should be used. When only a small number of cases is
presented, the respective values or time course can be pre-
sented individually.
(36) Data on Neonatal Encephalopathy obtained from subjects
receiving a vaccine should be compared with those obtained
from an appropriately selected and documented control
group(s) to assess background rates of hypersensitivity in
non-exposed populations, and should be analysed by study
arm and dose where possible, e.g. in prospective clinical
trials.
3.3. Data presentation
These guidelines represent a desirable standard for the
presentation and publication of data on Neonatal Encephalopathy
following maternal immunisation to allow for comparability of
data, and are recommended as an addition to data presented
for the specific study question and setting. Additionally, it isgiven event could be determined.
12 If the evidence available for an event is insufficient because information is
missing, such an event should be categorised as ‘‘Reported Neonatal Encephalopathy
with insufficient evidence to meet the case definition”.
13 An event does not meet the case definition if investigation reveals a negative
finding of a necessary criterion (necessary condition) for diagnosis. Such an event
should be rejected and classified as ‘‘Not a case of Neonatal Encephalopathy”.
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sentation and publication of randomised controlled trials, system-
atic reviews, and meta-analyses of observational studies in
epidemiology (e.g. statements of Consolidated Standards of
Reporting
Trials (CONSORT), of improving the quality of reports of meta-
analyses of randomised controlled trials (QUORUM), and of meta-
analysis Of Observational Studies in Epidemiology (MOOSE),
respectively).
(37) All reported events of Neonatal Encephalopathy should be
presented according to the categories listed in guideline 31.
(38) Data on Neonatal Encephalopathy events should be pre-
sented in accordance with data collection guidelines 1–24
and data analysis guidelines 31–36
(39) Terms to describe Neonatal Encephalopathy such as ‘‘low-
grade”, ‘‘mild”, ‘‘moderate”, ‘‘high”, ‘‘severe” or ‘‘significant”
are highly subjective, prone to wide interpretation, and
should be avoided, unless clearly defined.
(40) Data should be presented with numerator and denominator
(n/N) (and not only in percentages), if available.
Although immunisation safety surveillance systems denomina-
tor data are usually not readily available, attempts should be made
to identify approximate denominators. The source of the denomi-
nator data should be reported and calculations of estimates be
described (e.g. manufacturer data like total doses distributed,
reporting through Ministry of Health, coverage/population based
data, etc.).
(41) The incidence of cases in the study population should be
presented and clearly identified as such in the text.
(42) If the distribution of data is skewed, median and range are
usually the more appropriate statistical descriptors than a
mean. However, the mean and standard deviation should
also be provided.
(43) Any publication of data on Neonatal encephalopathy should
include a detailed description of the methods used for data
collection and analysis as possible. It is essential to specify:
 The study design;
 The method, frequency and duration of monitoring for Acute
Neonatal encephalopathy;
 The trial profile, indicating participant flow during a study
including drop-outs and withdrawals to indicate the size and
nature of the respective groups under investigation;
 The type of surveillance (e.g. passive or active surveillance);
 The characteristics of the surveillance system (e.g. population
served, mode of report solicitation);
 The search strategy in surveillance databases;
 Comparison group(s), if used for analysis;
 The instrument of data collection (e.g. standardised question-
naire, diary card, report form);
 Whether the day of immunisation was considered ‘‘day one” or
‘‘day zero” in the analysis;
 Whether the date of onset (see footnote 3) and/or the date of
first observation (see footnote 4) and/or the date of diagnosis
(see footnote 5) was used for analysis; and
 Use of this case definition for Neonatal encephalopathy, in the
abstract or methods section of a publication.1414 Use of this document should preferably be referenced by referring to the
respective link on the Brighton Collaboration website (http://www.brightoncollabo-
ration.org).Disclaimer
The findings, opinions and assertions contained in this consen-
sus document are those of the individual scientific professional
members of the working group. They do not necessarily represent
the official positions of each participant’s organisation (e.g., gov-
ernment, university, or corporation). Specifically, the findings and
conclusions in this paper are those of the authors and do not nec-
essarily represent the views of their respective institutions.
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